Please note that this webinar was recorded in 2017. All AMPEDTM content is reviewed and approved annually by the Training & Education Committee as relevant and accurate, but new data may now be available and new studies may have since been published.
AMP Education is constantly updating these educational offerings, so keep checking back at educate.amp.org for new content, content updates, and information on cutting-edge molecular pathology research and applications.
Description:
Precision oncology relies on targeted drugs such as kinase inhibitors that are presently administered based on molecular profiles obtained from surgical or bioptic tissue samples. The inherent ability of human tumours to molecularly evolve in response to drug pressures represents a daunting diagnostic challenge. Circulating free DNA (cfDNA) released from primary and metastatic lesions can be used to draw molecular maps that can be continuously updated to match each patient's tumour evolution, in order to help with the clinical-decision making.
Learning Objectives:
- Improve personalized medicine for cancer patients based upon detailed and complete molecular characterization of each patient's tumor.
- Employ liquid biopsy analysis in clinical settings.
- Adapt clinical treatment of cancer patients to the tumor evolution under different treatment regimens.
Speaker: Mariangela Russo, PhD
Host: Mark Ewalt, MD
Duration: 0.75 hr
Level of Instruction: Basic
Recording Date: August 3, 2017
Note: Join the AMP Family for discounted access to the most current educational resources!
All sales are final. No refunds will be issued.
No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.
